BioLife Solutions - BLFS Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1 year price objectives for BioLife Solutions' stock. Their BLFS share price forecasts range from $29.00 to $34.00. On average, they predict the company's share price to reach $31.20 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts.

BioLife Solutions' stock was trading at $18.20 at the beginning of 2023. Since then, BLFS shares have increased by 29.1% and is now trading at $23.50.
View the best growth stocks for 2023 here.

BioLife Solutions saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 2,330,000 shares, a drop of 5.7% from the December 31st total of 2,470,000 shares. Based on an average daily volume of 379,600 shares, the short-interest ratio is presently 6.1 days. Currently, 5.9% of the shares of the stock are short sold.
View BioLife Solutions' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our BLFS earnings forecast.

BioLife Solutions, Inc. (NASDAQ:BLFS) released its quarterly earnings results on Wednesday, November, 9th. The medical equipment provider reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The medical equipment provider earned $40.75 million during the quarter, compared to analysts' expectations of $41.63 million. BioLife Solutions had a negative net margin of 67.70% and a negative trailing twelve-month return on equity of 7.50%.

BioLife Solutions issued an update on its FY 2022 earnings guidance on Saturday, January, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $161.90 million-$161.90 million, compared to the consensus revenue estimate of $160.92 million.

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

BioLife Solutions' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Stephens Investment Management Group LLC (0.92%), Peregrine Capital Management LLC (0.67%), Stephens Inc. AR (0.34%), Yousif Capital Management LLC (0.05%), Comerica Bank (0.05%) and Greenwood Capital Associates LLC (0.05%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends.

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLFS stock can currently be purchased for approximately $23.50.

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $1.01 billion and generates $119.16 million in revenue each year. The medical equipment provider earns $-7,640,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.

The company employs 432 workers across the globe.

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.